Chotosan, a Kampo Formula, Ameliorates Chronic Cerebral Hypoperfusion-Induced Deficits in Object Recognition Behaviors and Central Cholinergic Systems in Mice

Access this Article



We previously demonstrated that the <i>Kampo</i> formula <i>chotosan</i> (CTS) ameliorated spatial cognitive impairment via central cholinergic systems in a chronic cerebral hypoperfusion (P2VO) mouse model. In this study, the object discrimination tasks were used to determine if the ameliorative effects of CTS on P2VO-induced cognitive deficits are a characteristic pharmacological profile of this formula, with the aim of clarifying the mechanisms by which CTS enhances central cholinergic function in P2VO mice. The cholinesterase inhibitor tacrine (THA) and <i>Kampo</i> formula <i>saikokeishito</i> (SKT) were used as controls. P2VO impaired object discrimination performance in the object recognition, location, and context tests. Daily administration of CTS (750 mg/kg, p.o.) and THA (2.5 mg/kg, i.p.) improved the object discrimination deficits, whereas SKT (750 mg/kg, p.o.) did not. In <i>ex vivo</i> assays, tacrine but not CTS or SKT inhibited cortical cholinesterase activity. P2VO reduced the mRNA expression of m<sub>3</sub> and m<sub>5</sub> muscarinic receptors and choline acetyltransferase but not that of other muscarinic receptor subtypes in the cerebral cortex. Daily administration of CTS and THA but not SKT reversed these expression changes. These results suggest that CTS and THA improve P2VO-induced cognitive impairment by normalizing the deficit of central cholinergic systems and that the beneficial effect on P2VO-induced cognitive deficits is a distinctive pharmacological characteristic of CTS.<br>


  • Journal of Pharmacological Sciences

    Journal of Pharmacological Sciences 103(4), 360-373, 2007-04-20

    The Japanese Pharmacological Society

References:  43

Cited by:  6


  • NII Article ID (NAID)
  • Text Lang
  • Article Type
    Journal Article
  • ISSN
  • NDL Article ID
  • NDL Source Classification
  • NDL Call No.
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top